Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 PF-04965842 Monotherapy in Moderate to Severe Atopic Dermatitis
2018-001136-21Phase 3Completed
- Sponsor
- Pfizer
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing PF-04965842 monotherapy with Placebo (2 arms). Primary endpoint: Co-primary efficacy endpoints. Started Aug 2018; status: completed.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2018-001136-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001136-21.